Resources from the same session
Optimal positioning and sequencing of EGFR E20I inhibitors: Research perspectives for (neo-)adjuvant use and 1st line of advanced disease
Presenter: P. A. Jänne, US
Session: Session 5 – Optimising use of EGFR E20I mutations
Resources:
Slides
Webcast
The role of Molecular Tumour Boards for optimal interpretation of molecular reports and tailoring of therapeutic strategies in patients with advanced NSCLC
Presenter: D. S. W. Tan, SG
Session: Session 5 – Optimising use of EGFR E20I mutations
Resources:
Webcast